Association between common genetic variant of HRH2 and gastric cancer risk

Arisawa,Tomiyasu; Tahara,Tomomitsu; Ozaki,Kazuaki; Matsue,Yasuhiro; Minato,Takahiro; Yamada,Hideto; Nomura,Tomoe; Hayashi,Ranji; Matsunaga,Kazuhiro; Fukumura,Atsushi; Nakamura,Masakatsu; Toshikuni,Nobuyuki; Shiroeda,Hisakazu; Shibata,Tomoyuki

doi:10.3892/ijo.2012.1482

Association between common genetic variant of HRH2 and gastric cancer risk

Authors:
- Tomiyasu Arisawa
- Tomomitsu Tahara
- Kazuaki Ozaki
- Yasuhiro Matsue
- Takahiro Minato
- Hideto Yamada
- Tomoe Nomura
- Ranji Hayashi
- Kazuhiro Matsunaga
- Atsushi Fukumura
- Masakatsu Nakamura
- Nobuyuki Toshikuni
- Hisakazu Shiroeda
- Tomoyuki Shibata
View Affiliations

Affiliations: Department of Gastroenterology, Kanazawa Medical University, Uchinada-machi, Ishikawa 920-0293, Japan, Department of Gastroenterology, Fujita Health University, Kutsukake-cho, Toyoake 470-1192, Japan
Published online on: May 17, 2012 https://doi.org/10.3892/ijo.2012.1482
Pages: 497-503

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histamine plays important physiological roles in the upper gastrointestinal tract and acts via the H2 receptor. The -1018 G>A (rs2067474) in an enhancer element of the promoter and non-synonymous rs79385261 (Asn46Thr) were identified in HRH2. We attempted to clarify the associations of these polymorphisms with gastric carcinogenesis. The study was performed in 321 patients with gastric cancer and 599 subjects with no evidence of gastric malignancies on upper gastroduodenal endoscopy. The genotypes were determined using a one-tube multiplex PCR-SSCP method. The degree of gastritis was assessed in 496 subjects and serum pepsinogen (PG) I/II levels were measured in 124 subjects without gastric cancer. The minor allele of Asn46Thr could not be detected. The frequencies of the -1018 A allele in the non-GC and GC groups were 13.5% and 8.26%, respectively (p=0.00077). Overall, -1018 GG homozygotes had an increased risk for developing gastric cancer (OR 1.68; 95% CI 1.17-2.42; p=0.0052), especially intestinal type cancer (OR 1.94; 95% CI 1.23-3.08; p=0.0047). In subjects aged >60 years, the adjusted risk for gastric cancer among individuals who were -1018 GG homozygotes was 1.87 (range 1.19-2.93; p=0.0065) compared with A carriers. In the gastric cancer cases located in the antrum and at comparative advanced stage, -1018 GG homozygosity was a significantly increased risk factor. In subjects >60 years, the metaplasia score was significantly higher in -1018 GG homozygotes than A carriers. Both atrophy and metaplasia scores were significantly increased with age only in -1018 GG homozygotes. The PG I/II ratio was significantly decreased in H. pylori positive GG homozygotes than negative GG homozygotes and positive A carriers. Our results suggest that -1018 GG homozygosity of HRH2 may be associated with the severity of gastric mucosal atrophy. This genotype has an increased risk for the subsequent development of gastric cancer, especially intestinal type, at advanced age.

View Figures

View References

1	Murray CJ and Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 349:1436–1442. 1997. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2002. View Article : Google Scholar
3	Correa P: Human gastric carcinogenesis: a multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 52:6735–6740. 1992.
4	Suerbaum S and Michetti P: Helicobacter pylori infection. N Engl J Med. 347:1175–1186. 2002. View Article : Google Scholar : PubMed/NCBI
5	Covacci A, Telford JL, Del GG, Giudice GD, Parsonnet J and Rappuoli R: Helicobacter pylori virlence and genetic geography. Science. 284:1328–1333. 1999. View Article : Google Scholar : PubMed/NCBI
6	Uemura N, Okamoto S, Yamamoto S, et al: Helicobacter pylori infection and development of gastric cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar
7	El-Omar EM, Carrington M, Chow WH, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 404:398–402. 2000. View Article : Google Scholar : PubMed/NCBI
8	Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M and Sugimura H: Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 123:92–105. 2002.
9	Machado JC, Figueiredo C, Canedo P, et al: A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology. 125:364–371. 2003. View Article : Google Scholar : PubMed/NCBI
10	Ohyauchi M, Imatani A, Yonechi M, et al: The polymorphism interleukin 8–251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut. 54:330–335. 2005.
11	Ohmiya N, Taguchi A, Mabuchi N, et al: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol. 24:4434–4440. 2006. View Article : Google Scholar : PubMed/NCBI
12	Tahara T, Arisawa T, Wang F, et al: Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci. 98:1790–1794. 2007. View Article : Google Scholar : PubMed/NCBI
13	Arisawa T, Tahara T, Shibata T, et al: Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. Oncol Rep. 19:223–228. 2008.PubMed/NCBI
14	Shibata T, Tahara T, Hirata I and Arisawa T: Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum Immunol. 70:547–551. 2009. View Article : Google Scholar : PubMed/NCBI
15	Okubo M, Tahara T, Shibata T, et al: Association between common genetic variants in pre-microRNAs and gastric cancer risk in Japanese population. Helicobacter. 15:524–531. 2010. View Article : Google Scholar : PubMed/NCBI
16	Chen D, Aihara T, Zhao CM, Hakanson R and Okabe S: Differentiation of the Gastric Mucosa I. Role of histamine in control of function and integrity of oxyntic mucosa: 1. understanding gastric physiology through disruption of targeted genes. Am J Physiol Gastrointest Liver Physiol. 291:G539–G544. 2006. View Article : Google Scholar : PubMed/NCBI
17	Rangachari PK: Histamine: mercurial messenger in the gut. Am J Physiol. 262:G1–G13. 1992.PubMed/NCBI
18	Hill SJ, Ganellin CR, Timmerman H, et al: International Union of Pharmacology. XIII Classification of histamine receptors. Pharmacol Rev. 49:253–278. 1997.PubMed/NCBI
19	Black J, Duncan W and Durant D: Definition and antagonism of histamine H2-receptors. Nature. 236:385–390. 1972. View Article : Google Scholar : PubMed/NCBI
20	Jones DB, Howden CW, Burget DW, et al: Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut. 28:1120–1127. 1987. View Article : Google Scholar : PubMed/NCBI
21	Marshall BJ and Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulcer. Lancet. 1:1311–1315. 1984. View Article : Google Scholar : PubMed/NCBI
22	McColl KEL, El-Omar E and Gillen D: Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull. 54:121–138. 1998. View Article : Google Scholar : PubMed/NCBI
23	Courillon-Mallet A, Launay JM, Roucayrol AM, et al: Helicobacter pylori infection: physiopathologic implication of N-methylhistamine. Gastroenterology. 108:959–966. 1995. View Article : Google Scholar : PubMed/NCBI
24	McGowan CC, Cover TL and Blaser MJ: Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology. 110:926–938. 1996. View Article : Google Scholar : PubMed/NCBI
25	Bodger K and Crabtree JE: Helicobacter pylori and gastric inflammation. Br Med Bull. 54:139–150. 1998. View Article : Google Scholar : PubMed/NCBI
26	Mancama D, Arranz MJ, Munro J, et al: Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci Lett. 333:207–211. 2002. View Article : Google Scholar : PubMed/NCBI
27	Garcia-Martin E, Ayuso P, Luengo A, Martinez C and Agundez JAG: Genetic variability of histamine receptors in patients with Parkinson's disease. BMC Med Genet. 9:152008.PubMed/NCBI
28	Arisawa T, Tahara T, Shibata T, et al: The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol. 28:44–49. 2008. View Article : Google Scholar : PubMed/NCBI
29	Dixon MF, Genta RM, Yardley JH and Correa P: Classification and grading of gastritis: the updated Sydney system. Am J Surg Pathol. 20:1161–1181. 1996. View Article : Google Scholar : PubMed/NCBI
30	Kang GH, Shim YH, Jung HY, Kim WH, Ro JY and Rhyu MG: CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 61:2847–2851. 2001.PubMed/NCBI
31	Pestov DG, Strezoska Z and Lau LF: Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition. Mol Cell Biol. 21:4246–4255. 2001. View Article : Google Scholar : PubMed/NCBI
32	Ito C, Morisset S, Krebs MO, et al: Histamine H2 receptor gene variants: lack of association with schizophrenia. Mol Psychiatry. 5:159–164. 2000. View Article : Google Scholar : PubMed/NCBI
33	Fox JG, Rogers AB, Ihrig M, et al: Helicobacter pylori-associated gastric cancer in INSGAS mice is gender specific. Cancer Res. 63:942–950. 2003.PubMed/NCBI
34	Wang TC, Dangler CA, Chen D, et al: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 118:36–47. 2000. View Article : Google Scholar : PubMed/NCBI
35	Kuipers EJ, Uyterlinde AM, Pena AS, et al: Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 90:1401–1406. 1995.PubMed/NCBI
36	Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 334:1018–1022. 1996. View Article : Google Scholar : PubMed/NCBI
37	Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A and Brandtzaeg P: Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux esophagitis after treatment with lansoprazole. Gut. 41:740–747. 1997. View Article : Google Scholar : PubMed/NCBI
38	Takaishi S, Cui G, Frederick DM, et al: Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology. 128:1965–1983. 2005. View Article : Google Scholar : PubMed/NCBI
39	Poynter D and Selway SA: Neuroendocrine cell hyperplasia and neuroendocrine carcinoma of the rodent fundic stomach. Mutat Res. 248:303–319. 1991. View Article : Google Scholar : PubMed/NCBI
40	Brenna E, Swarts HG, Klaassen CH, De Pont JJ and Waldum HL: Evaluation of the trophic effect of longterm treatment with the histamine H2 receptor antagonist loxtidine on rat oxyntic mucosa by differential counting of dispersed cells. Gut. 35:1547–1550. 1994. View Article : Google Scholar : PubMed/NCBI
41	Cui G, Takaishi S, Ai W, et al: Gastrin-induced apoptosis contributes to carcinogenesis in the stomach. Lab Invest. 86:1037–1051. 2006. View Article : Google Scholar : PubMed/NCBI
42	Hunyady B, Zolyomi A, Czimmer J, et al: Expanded parietal cell pool in transgenic mice unable to synthesize histamine. Scand J Gastroenterol. 38:133–140. 2003.PubMed/NCBI
43	Ohtsu H and Watanabe T: New functions of histamine found in histidine decarboxylase gene knockout mice. Biochem Biophys Res Commun. 305:443–447. 2003. View Article : Google Scholar : PubMed/NCBI
44	Fukushima Y, Matsui T, Saitoh T, et al: Unique roles of G protein-coupled histamine H2 and gastrin receptors in growth and differentiation of gastric mucosa. Eur J Pharmacol. 502:243–252. 2004. View Article : Google Scholar : PubMed/NCBI
45	Lauren P: The two histologic main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI
46	Go MF: Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 16:3–15. 2002. View Article : Google Scholar : PubMed/NCBI
47	Tonnesen H, Knigge U, Bulow S, et al: Effect of cimetidine on survival after gastric cancer. Lancet. 2:990–992. 1988. View Article : Google Scholar : PubMed/NCBI
48	Griswold DE, Alessi S, Badger AM, Poste G and Hanna N: Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol. 132:3054–3057. 1984.PubMed/NCBI
49	Kikuchi Y, Oomori K, Kizawa I and Kato K: Augmented natural killer activity in ovarian cancer patients treated with cimetidine. Eur J Cancer Clin Oncol. 22:1037–1043. 1986. View Article : Google Scholar : PubMed/NCBI
50	Watson SA, Wilkinson LJ, Robertson JR and Hardcastle JD: Effect of histamine on the growth of human gastro-intestinal tumours: reversal by cimetidine. Gut. 34:1091–1096. 1993. View Article : Google Scholar : PubMed/NCBI